CD20 CAR Lentivirus

Focused on CD20 positive malignancies our CD20 CAR Lentivirus is designed to provide unprecedented solutions for diseases such as Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia to meet our mission of addressing Hematological malignancies.

Check the CAR-T Cell Preparation-Lentivirus Packaging Service

Order information

Description

CD20 CAR Lentivirus offered by GeneMedi represents our determination to design complex therapies for CD20 positive hematological malignancies. Another B7-Like protein or B cell receptor, which is resistant to CD20 is a protein that appears mostly on the surface of B cells and contributes towards diseases such as NHL and CLL among others. That is why the CARS procedure, by which patients’ cells are genetically modified to target CD20, can be a hope for treatment of these cancers that can be resistant to traditional therapy.

Our CD20 CAR Lentivirus redesigns T cells by transferring a CAR structure that selectively binds with efficiency to CD20 antigen. It is critical in this regard because it helps to overcome off target effects, while improving the antitumor activity of the T cells. _patients with non-Hodgkin lymphoma and CLL can often be limited by few treatment options and thus, our lentivirus can reinvent the treatment for these diseases.

At GeneMedi, it is very much appreciated that achieving laboratory success in clinical applications is not a simple process. Hence, the CD20 CAR Lentivirus is developed under great standard operating procedures to ensure that our product is replicable and efficient for application by researchers and medical practitioners. The lentivirus has high transduction efficiency and stable CAR expression, which is the prerequisite for constructing highly efficient CAR-T cell products for clinical application.